1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: Amgen positions for obesity and diabetes; BMS returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer’s crown?; Japan pharma firms cut jobs; and Sun Pharma seeks GLP-1 partner.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 August 2024, including: Amgen, Inc. positions for obesity and diabetes; Bristol Myers Squibb Company returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer AG’s crown?; Japan pharma firms cut jobs; and Sun Pharmaceutical Industries Ltd. seeks GLP-1 partner. 

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode: 

(Also see "Amgen Gets Into Position For MariTide Development" - Scrip, 6 August, 2024.)

(Also see "BMS Returns TIGIT Bispecific To Agenus Amid Pipeline Reshuffle" - Scrip, 5 August, 2024.)

(Also see "Kerendia Could Be Next Jewel In Bayer's Pharma Crown" - Scrip, 6 August, 2024.)

(Also see "Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts" - Scrip, 8 August, 2024.)

(Also see "Sun Seeks Partner For GLP-I Asset, Legal Challenge Clouds Alopecia Drug Launch" - Scrip, 5 August, 2024.)

Citeline · Scrip's Five Must-Know Things - 13 August 2024

Open Media

More from Alimentary/Metabolic

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry

 
• By Andrew McConaghie

The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.

Unicycive Approaches Its First Approval, But In A Competitive Space

 
• By Jessica Merrill

The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.

Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow

 
• By Andrew McConaghie

After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.

Novo Gets Its Own ‘Triple G’ Obesity Drug To Rival Lilly

 
• By Andrew McConaghie

The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.

More from Therapy Areas

Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow

 
• By Andrew McConaghie

After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By Joseph Haas

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Rybrevant/Lazcluze Survival Win Could Overcome Tagrisso’s Convenience Advantage

 
• By Alaric DeArment

J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.